by John Conrad | Jun 27, 2024 | Policy News
In a significant move to address longstanding issues of underrepresentation in medical research, the U.S. Food and Drug Administration (FDA) has released a draft guidance document aimed at increasing diversity in clinical trials. This much-anticipated guidance, titled...
by John Conrad | May 29, 2024 | Policy News
The FDA issued draft guidance outlining a new “platform designation” that companies can apply for as part of a broader initiative to modernize the agency’s approach to medicines developed using cutting-edge genetic technologies. This guidance proves...
by John Conrad | May 28, 2024 | Policy News
The Illinois General Assembly returns to Springfield today to approved a $53 billion state budget for fiscal year 2024 after a marathon negotiating session over the Memorial Day weekend. The budget framework passed by the Senate includes over $750 million in various...
by John Conrad | May 13, 2024 | Policy News
U.S. legislation could disrupt drug supply chain This week’s Policy Highlight looks at the BIOSECURE Act, a bill currently being debated in Congress. The Act aims to limit collaboration between U.S. companies and certain Chinese firms in the biotechnology...
by John Conrad | Mar 21, 2024 | Policy News
Calling all Illinois BioPharma startups! Join iBIO for the annual BIO Fly-In in Washington D.C. on April 16th & 17th. This is a fantastic opportunity to connect with policymakers and champion the life sciences industry! What is the BIO Fly-In? This event brings...
by John Conrad | Jan 2, 2024 | Policy News
We want to take a moment to recognize Congressman Brad Schneider for his leadership and advocacy on behalf of the biopharmaceutical industry. His recent letter to the U.S. Trade Representative opposing the proposed expansion of the waiver of IP rights for COVID...
